abacavir + stavudine + efavirenz

This drug is a **three-drug antiretroviral combination** consisting of **abacavir**, **stavudine**, and **efavirenz**, all of which are used for the treatment of HIV-1 infection. - **Abacavir** and **stavudine** are **synthetic nucleoside reverse transcriptase inhibitors (NRTIs)**, while **efavirenz** is a **non-nucleoside reverse transcriptase inhibitor (NNRTI)**. - Together, they act to **suppress HIV-1 replication** by inhibiting reverse transcriptase, an essential enzyme for HIV replication. - This combination is used as part of a highly active antiretroviral therapy (HAART) regimen, particularly where fixed-dose combinations of these three drugs are not available. - Each component has its own safety and adverse effect profile: abacavir has a risk of hypersensitivity reactions, stavudine is linked to lactic acidosis and neuropathy, and efavirenz is known for CNS-related adverse effects such as dizziness and vivid dreams[2][3]. - The combination is generally administered at fixed doses orally, and is sometimes co-packaged for convenience, but not available in a single fixed-dose branded tablet[3]. - This combination, while historically used, is not recommended as a preferred combination in current guidelines due to concerns about toxicity, particularly with stavudine.